Apart from driving tumourigenesis, mutant KRAS can also affect the tumour microenvironment (TME) by regulating cytokine release, recruitment of immune cells to the tumour sites for enhanced inflammatory responses as well as facilitating immune escape [27, 28]. Here, KRAS is linked to neoplasm.